Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Kevin J Harrington"'
Autor:
Clifton D. Fuller, Baukelien van Triest, Bruce D. Minsky, Rob H N Tijssen, Joel W. Goldwein, Stella Mook, Kevin J. Harrington, John P. Christodouleas, Uulke A. van der Heide, Robert Huddart, Ananya Choudhury, Kristina Orrling, Sophie R de Mol van Otterloo, Robbert J.H.A. Tersteeg, Susan Lalondrelle, Dave Eggert, Anna M. Kirby, Chia-Lin Tseng, Beth Erickson, Uwe Oelfke, Hafid Akhiat, Marlies E. Nowee, K.J. Brown, Claire McCann, Corinne Faivre-Finn, Erwin L. A. Blezer, Emma Hall, Lois A. Daamen, Helena M. Verkooijen, Martijn Intven, Christopher J. Schultz, Alison Tree, Shaista Hafeez, Marielle E.P. Philippens, Arjun Sahgal, William A. Hall
Publikováno v:
Int J Radiat Oncol Biol Phys
International Journal of Radiation Oncology-Biology-Physics, 111(4), 867-875. ELSEVIER SCIENCE INC
International Journal of Radiation Oncology-Biology-Physics, 111(4), 867-875. ELSEVIER SCIENCE INC
Purpose: High-field magnetic resonance-linear accelerators (MR-Linacs), linear accelerators combined with a diagnostic magnetic resonance imaging (MRI) scanner and online adaptive workflow, potentially give rise to novel online anatomic and response
Autor:
Dorothy M. Gujral, Kevin J. Harrington, Win Soe, Aisha Miah, M. Emson, David Bernstein, Katie Wood, James P Morden, Amen Sibtain, Matthew Beasley, Deborah Gardiner, Nachi Palaniappan, Audrey Cook, Teresa Guerrero Urbano, Shelia Fisher, Tom Roques, M. Rizwanullah, Mehmet Sen, Paul Sanghera, Emma Hall, Christopher D Scrase, Vivian P Cosgrove, Christopher M. Nutting, Clare Griffin, Shanmugasundaram Ramkumar, Elizabeth Junor, Shreerang Bhide, Catherine M West, Bernadette Foran, Hisham Mehanna
Publikováno v:
European Journal of Cancer. 153:242-256
Background Radical (chemo)radiotherapy offers potentially curative treatment for patients with locally advanced laryngeal or hypopharyngeal cancer. We aimed to show that dose-escalated intensity-modulated radiotherapy (DE-IMRT) improved locoregional
Autor:
Burak Gumuscu, Kevin J. Harrington, Hoi-Shen Radcliffe, Lillian L. Siu, Wendy Snyder, Danny Rischin, Beatriz Castelo Fernandez, Ezra E.W. Cohen, Jason Chesney, Anthony Kong, Jonathan D. Cheng, Nicolas Mach
Publikováno v:
Clinical Cancer Research, Vol. 26, No 19 (2020) pp. 5153-5161
Purpose: The prognosis for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is poor, and only a minority of patients benefit from checkpoint immunotherapy. Talimogene laherparepvec (T-VEC), an oncolytic immunoth
Autor:
Jérôme Fayette, Vijayvel Jayaprakash, Kevin J. Harrington, Robert L. Ferris, Li Li, Maura L. Gillison, Peter Brossart, Nabil F. Saba, Joël Guigay, Lisa Licitra, Naomi Kiyota, George R. Blumenschein
Publikováno v:
Oral oncology
Objectives: Many patients with squamous cell carcinoma of the head and neck (SCCHN) are ≥65 years old; comorbidities and other age-related factors may affect their ability to tolerate traditional chemotherapy. Nivolumab is the only immunotherapy to
Autor:
Lisa Pickering, Nalinie Joharatnam-Hogan, Fiona Kinnaird, Andrew Furness, Mary Wu, Daqi Deng, Sina Namjou, Sarah Sarker, Aljosja Rogiers, Aida Murra, Justine Korteweg, Nicholas van As, Nicholas C. Turner, Anna Robinson, Joanne Droney, Kema Peat, Shaman Jhanji, Mike Gavrielides, Isla Leslie, Lauren Dowdie, Tara Foley, Christina Messiou, Natalie Ash, Taja Barber, Andrea Emslie-Henry, Simon Caidan, Karolina Rzeniewicz, Katalin A. Wilkinson, Ruth Harvey, Annika Fendler, Kate Tatham, Andreas M. Schmitt, Sunil Iyengar, Shreerang Bhide, Kayleigh Kelly, David L.V. Bauer, Benjamin Shum, Kim Edmonds, Gail Gardner, Scott Shepherd, Mark Ethell, Laura Amanda Boos, Liam Welsh, Robert J. Wilkinson, Lucy Holt, Alicia Okines, William Gordon, James I. MacRae, Maddalena Cerrone, Kevin J. Harrington, Mary Mangwende, Hamid Ahmod, Olivia Curtis, Emma Nicholson, Darren Murray, Susana Banerjee, Firza Gronthoud, Bhavna Oza, Naureen Starling, Wenyi Xie, Alison Reid, Karla Lingard, Ana Agua-Doce, Charles Swanton, Sacheen Kumar, Lewis Au, Michael Howell, James Larkin, Camille L. Gerard, Emma C Wall, Jessica Bazin, Ian Chau, Robin L. Jones, Fiona Byrne, Robyn L. Shea, Denise Kelly, Nadia Yousaf, Steve Gamblin, Kate Young, Sonia Gandhi, Susanna Walker, Eleanor Carlyle, Javier Pascual, David Cunningham, Samra Turajlic, Clemency Stephenson, Zayd Tippu, Gavin Kelly, Mary O'Brien, Sheima Farag, Molly O’Flaherty, George Kassiotis, Wanyuan Cui, Justin Mencel, Lyra Del Rosario, Simon Rodney
Publikováno v:
Nature cancer
Nature Cancer
Nature Cancer
Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f90b7e7f14703f40105aa2f1e5740b1a
https://doi.org/10.21203/rs.3.rs-916303/v1
https://doi.org/10.21203/rs.3.rs-916303/v1
Autor:
Kate Newbold, Shreerang Bhide, Alan Melcher, Amy Trinh, KH Wong, Pablo Nenclares, Lucinda Gunn, Heba Soliman, Mateo Bover, Kevin J. Harrington, Christopher M. Nutting, Isla Leslie, Derfel Ap Dafydd
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
BackgroundPrevious studies have suggested that inflammatory markers (neutrophil-to-lymphocyte ratio (NLR), lactate dehydrogenase (LDH) and fibrinogen) are prognostic biomarkers in patients with a variety of solid cancers, including those treated with
Autor:
Robert H.I. Andtbacka, Frances A. Collichio, Gerald Downey, Kevin J. Harrington, Howard L. Kaufman, Mark R. Middleton, Katarina Ӧhrling
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and Switzerland. We report the final planned analysis of OPTiM, a randomized open-label phase III trial in patients with unresectable stage IIIB
Autor:
Mansour T. A. Sharabiani, Paul Carter, S.A. Bhide, Kevin J. Harrington, R. Shaikh, Isaac Garcia-Murillas, D.M. Allin, Katie L. Newbold, Khin Thway, D. Kim, D. Gonzales-de-Castro, Ben O'Leary, Mike Hubank
Publikováno v:
European Journal of Cancer. 103:165-175
Background Conventional biomarkers in thyroid cancer are not disease specific and fluctuate in advanced disease, making interpretation difficult. Circulating tumour DNA (ctDNA) has been shown to be a useful biomarker in other solid tumours. This is a
Autor:
Jonathan D. Cheng, Barbara Burtness, José Dinis, Misoo C. Ellison, Nicolas Mach, Christophe Le Tourneau, Diana Chirovsky, Ainara Soria, Ramona F. Swaby, Lisa Licitra, Kevin J. Harrington, Denis Soulières, Myung-Ju Ahn, Ranee Mehra, Ezra E.W. Cohen, Jean-Pascal Machiels
Publikováno v:
Journal of the National Cancer Institute, Vol. 113, no.2, p. 171-181 (2021)
J Natl Cancer Inst
Journal of the National Cancer Institute, vol 113, iss 2
Journal of the National Cancer Institute, Vol. 113, No 2 (2021) pp. 171-181
J Natl Cancer Inst
Journal of the National Cancer Institute, vol 113, iss 2
Journal of the National Cancer Institute, Vol. 113, No 2 (2021) pp. 171-181
Background Head and neck squamous cell carcinoma (HNSCC) affects health-related quality of life (HRQoL); few treatments have demonstrated clinically meaningful HRQoL benefit. KEYNOTE-040 evaluated pembrolizumab vs standard of care (SOC) in patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c605279800d9cce11c0a442019697bb
https://hdl.handle.net/2078.1/245855
https://hdl.handle.net/2078.1/245855
Autor:
Clare Hodgson, Andrew J Wallace, Robert Metcalf, Guy N J Betts, Brindley Sonal Hapuarachi, Laura Feeney, Tracy Hussell, Kevin J. Harrington, Helen Adderley, Samuel Rack, David H. J. Morgan
Publikováno v:
Adderley, H, Rack, S, Hapuarachi, B, Feeney, L, Morgan, D, Hussell, T, Wallace, A J, Betts, G, Hodgson, C, Harrington, K & Metcalf, R 2021, ' The utility of TP53 and PIK3CA mutations as prognostic biomarkers in salivary adenoid cystic carcinoma ', Oral Oncology, vol. 113, 105095 . https://doi.org/10.1016/j.oraloncology.2020.105095
OBJECTIVES: Despite wide excision and post-operative irradiation, loco-regional and/or metastatic recurrence is a significant clinical problem in salivary adenoid cystic carcinoma (SACC). Reliable biomarkers are required to tailor post-treatment surv